| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
30,030,000 |
| Market
Cap: |
487.69(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$16.24 - $16.24 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Bryan E. |
GC/Urovant Sciences, Inc. |
• – – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(124,447) |
0 |
|
- |
|
| Haag-Molkenteller Cornelia |
CMO/Urovant Sciences, Inc. |
• – – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(141,348) |
0 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,480) |
0 |
|
- |
|
| Kurstjens Sef |
Director |
– • – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,480) |
0 |
|
- |
|
| Johnston Walt |
See Remarks |
• – – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(109,139) |
0 |
|
- |
|
| Hindman James M. |
Director |
– • – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(9,000) |
0 |
|
- |
|
| Ocampo Christine |
PAO; CAO/Urovant Sciences,Inc. |
• – – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(78,781) |
0 |
|
- |
|
| Potter Myrtle S |
Director |
– • – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(21,480) |
0 |
|
- |
|
| Robinson James A. Jr. |
PEO;CEO/Urovant Sciences, Inc. |
• • – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(8,385) |
0 |
|
- |
|
| Bansal Ajay |
See Remarks |
• – – |
2021-03-29 |
4 |
D |
$0.00 |
$0 |
D/D |
(140,098) |
0 |
|
- |
|
| Robinson James A. Jr. |
PEO; CEO/Urovant Sciences, Inc |
• • – |
2021-01-10 |
4 |
D |
$16.11 |
$65,970 |
D/D |
(4,095) |
8,385 |
|
- |
|
| Haag-Molkenteller Cornelia |
CMO/Urovant Sciences, Inc. |
• – – |
2021-01-07 |
4 |
D |
$16.09 |
$93,483 |
D/D |
(5,810) |
141,348 |
|
- |
|
| Smith Bryan E. |
GC/Urovant Sciences, Inc. |
• – – |
2021-01-07 |
4 |
D |
$16.09 |
$76,604 |
D/D |
(4,761) |
124,447 |
|
- |
|
| Kurstjens Sef |
Director |
– • – |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
21,480 |
|
- |
|
| Potter Myrtle S |
Director |
– • – |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
21,480 |
|
- |
|
| Legault Pierre |
Director |
– • – |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
21,480 |
|
- |
|
| Hindman James M. |
Director |
– • – |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Johnston Walt |
SVP, Commercial, USI |
• – – |
2020-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
108,647 |
108,647 |
|
- |
|
| Ocampo Christine |
PAO;CAO/Urovant Sciences, Inc |
• – – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
44,346 |
77,179 |
|
- |
|
| Haag-Molkenteller Cornelia |
CMO/Urovant Sciences, Inc. |
• – – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
83,149 |
145,277 |
|
- |
|
| Bansal Ajay |
PFO;CFO/Urovant Sciences, Inc. |
• – – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
63,659 |
138,659 |
|
- |
|
| Smith Bryan E. |
GC/Urovant Sciences, Inc. |
• – – |
2020-05-01 |
4 |
A |
$0.00 |
$0 |
D/D |
77,606 |
127,606 |
|
- |
|
| Sumitovant Biopharma Ltd. |
10% Owner |
– – • |
2020-02-19 |
4 |
B |
$13.08 |
$1,350,510 |
I/I |
103,250 |
22,963,263 |
1.5 |
-22% |
|
| Smith Bryan E. |
GC/Urovant Sciences, Inc. |
• – – |
2020-02-19 |
4 |
D |
$13.08 |
$198,358 |
D/D |
(15,165) |
50,000 |
|
- |
|
| Smith Bryan E. |
GC/Urovant Sciences, Inc. |
• – – |
2020-02-19 |
4 |
D |
$13.08 |
$455,642 |
D/D |
(34,835) |
65,165 |
|
- |
|
221 Records found
|
|
Page 1 of 9 |
|
|
